Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15

Rhea-AI Summary

Silo Pharma (Nasdaq: SILO) announced a non-binding Letter of Intent dated Dec. 30, 2025 with Allucent (US) LLC to support Phase 1 clinical development of SPC-15 nasal spray.

The LOI covers planning for two planned Phase 1 studies in healthy subjects: an open-label Single Ascending Dose (SAD) study and an open-label Multiple Ascending Dose (MAD) study. Allucent and Silo intend to negotiate a Master Services Agreement and project-specific Work Order covering clinical operations, pharmacovigilance, data management, biostatistics, clinical pharmacology modeling & simulation, and medical writing.

The LOI outlines proposed payment terms, including an upfront amount for direct service fees and pass-through costs to be reconciled against final invoices. Management described the LOI as a potential step toward generating safety and pharmacokinetic data for SPC-15.

Key Figures

Planned Phase 1 studies 2 studies Open-label SAD and MAD SPC-15 trials in healthy subjects

Development phase Phase 1 Initial clinical development program for intranasal SPC-15

Price change -8.26% Move over the last 24 hours before this news

52-week range $0.334 – $3.3699 Current price sits near the 52-week low

Market Reality Check

$0.3356 Last Close

Volume Volume 215,144 is about 1.7x the 20-day average of 126,497, indicating elevated trading interest ahead of this update. high

Technical Shares trade below the 200-day MA at 0.68 and sit 90.08% under the 52-week high of 3.3699, near the 0.334 52-week low.

Peers on Argus 1 Up

SILO is down 8.26% while peers show mixed moves (e.g., ARTL -15.65%, CERO +11.53%, ENSC -5.61%). Momentum scanner only flags SXTP up 10.11%, suggesting today’s action in SILO is more stock-specific than broad biotech sector rotation.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 17	Allucent partnership	Positive	-1.1%	Allucent selected to support planned 2026 IND for SPC-15 Phase 1.
Oct 29	Crypto treasury move	Positive	-1.9%	Selection of Alphaledger T12 Fund for tokenized RWA investment strategy.
Oct 23	SPC-15 and crypto update	Positive	+3.2%	Positive SPC-15 safety data plus launch of digital assets treasury program.
Oct 08	Bitcoin purchase	Positive	-1.4%	Initial strategic Bitcoin purchase as part of multi-chain asset growth plan.
Oct 06	RSC token acquisition	Positive	-2.2%	Acquisition of ResearchCoin tokens to gain DeSci exposure via crypto treasury.

Pattern Detected

Recent news often skews positive but has more frequently been followed by negative price reactions, with only one clear alignment between upbeat news and a rising share price.

Recent Company History

Over the last few months, Silo has balanced PTSD drug development with a growing crypto treasury strategy. Clinical milestones for SPC-15, including IND-enabling work and safety/toxicology updates, appeared alongside digital-asset initiatives in Bitcoin, Ethereum, Solana and RSC. Market reactions to these updates were modest, with most news moving the stock within single digits. Today’s LOI to support Phase 1 SPC-15 studies builds directly on prior Allucent collaboration and earlier clinical readiness updates from October–November 2025.

Market Pulse Summary

This announcement marks a key execution step, transitioning SPC-15 from preclinical work into planned Phase 1 SAD and MAD studies with a global CRO. It builds on prior IND-enabling toxicology and safety milestones and formalizes support across clinical operations, pharmacovigilance, data management, and modeling. Investors may watch for finalized service agreements, actual trial initiation, and any updates on financing capacity or Nasdaq listing risk flagged in recent SEC filings as the program advances.

Key Terms

single ascending dose medical

"an Open-Label, Single Ascending Dose (SAD) study and an Open-Label..."

A single ascending dose is a method used in testing new medicines where small amounts are given to participants, gradually increasing each time to find the safest and most effective dose. For investors, it provides important information about a drug’s safety and potential, helping gauge the progress and prospects of a pharmaceutical development.

multiple ascending dose medical

"Single Ascending Dose (SAD) study and an Open-Label, Multiple Ascending Dose (MAD) study."

A multiple ascending dose is a method used in testing new medicines where small groups of people receive gradually larger amounts of the drug over time. This approach helps researchers find the safest and most effective dose without causing too many side effects. For investors, it signals ongoing steps in drug development that can impact a company's potential success or approval prospects.

clinical research organization medical

"Allucent (US) LLC (“Allucent”), a global clinical research organization (CRO), to provide..."

A clinical research organization (CRO) is a company that manages and runs human studies for medicines, medical devices and diagnostics on behalf of developers and sponsors. Think of a CRO as an outsourced project manager and contractor for testing — they recruit patients, collect data, handle regulatory paperwork and keep studies on schedule. Investors watch CROs because their quality and capacity affect development speed, cost and regulatory risk, which in turn influence when and whether products reach the market.

pharmacovigilance medical

"across clinical operations, pharmacovigilance, data management, biostatistics..."

Pharmacovigilance is the process of monitoring and assessing the safety of medicines after they are on the market, ensuring that any side effects or risks are identified and managed. For investors, it matters because it helps ensure that pharmaceutical companies maintain safe products, which can influence a company’s reputation, regulatory approval, and financial stability over time.

biostatistics medical

"across clinical operations, pharmacovigilance, data management, biostatistics, clinical pharmacology..."

Biostatistics is the use of statistical methods to design medical studies, analyze biological and health data, and interpret the reliability of results from clinical trials and observational research. For investors, it is the tool that turns raw trial numbers into clear probabilities and confidence levels—much like a weather forecast turns measurements into a prediction—helping assess how credible study results are, estimate development risk, and value potential outcomes.

clinical pharmacology modeling & simulation medical

"data management, biostatistics, clinical pharmacology modeling & simulation, and medical writing..."

Clinical pharmacology modeling & simulation uses computer-based models to predict how a medicine moves through the body and produces effects, by combining data from lab tests, early human studies and known biology. For investors, it helps companies design safer, faster and smaller clinical trials and estimate the chances of a drug succeeding — like a flight simulator for drug development that reduces costly surprises and informs better go/no-go decisions.

AI-generated analysis. Not financial advice.

Planned SAD and MAD Studies Mark Key Clinical Inflection Point for Intranasal PTSD and Anxiety

SARASOTA, FL, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a diversified developmental stage biopharmaceutical and cryptocurrency treasury company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced it has entered into a non-binding Letter of Intent (“LOI”) with Allucent (US) LLC (“Allucent”), a global clinical research organization (CRO), to provide clinical research services for two planned Phase 1 studies evaluating its SPC-15 nasal spray in healthy subjects: an Open-Label, Single Ascending Dose (SAD) study and an Open-Label, Multiple Ascending Dose (MAD) study.

Allucent and Silo intend to negotiate a Master Services Agreement and project-specific Work Order to cover a comprehensive scope of activities across clinical operations, pharmacovigilance, data management, biostatistics, clinical pharmacology modeling & simulation, and medical writing to support execution and reporting of the Phase 1 program. The LOI also outlines proposed payment conditions, including an upfront amount for direct service fees and pass-through costs that would be reconciled against final project invoices.

“This letter of intent with Allucent could lead to a meaningful step forward in advancing SPC-15 into Phase 1 clinical development,” said Eric Weisblum, Chief Executive Officer of Silo Pharma. “Their global CRO expertise and integrated clinical capabilities appear to align well with our goal of efficiently generating high-quality safety and pharmacokinetic data. We believe this collaboration will allow us to execute our SAD and MAD studies with rigor and speed. Advancing SPC-15 remains a key priority as we strive to build long-term value across our pipeline.”

About SPC-15

SPC-15 is an investigational intranasal serotonin 5-HT4 receptor agonist being developed by Silo Pharma for stress-induced psychiatric conditions, primarily Post-Traumatic Stress Disorder (PTSD) and anxiety, using a special soft mist nasal spray delivery system for fast brain action. It's in preclinical stages, partnering with Columbia University, and aims for an accelerated FDA approval pathway (505(b)(2)) by leveraging biomarkers and novel delivery

About Silo Pharma

Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com

Forward-Looking-Statements

This news release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including statements pertaining to the intended use of proceeds from the offering, changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.

Contact

800-705-0120
investors@silopharma.com

FAQ

What did Silo Pharma announce about SPC-15 on December 30, 2025 (SILO)?

Silo announced a non-binding Letter of Intent with Allucent to support two planned Phase 1 studies (SAD and MAD) for SPC-15 nasal spray.

What Phase 1 studies are planned for SPC-15 under the Silo LOI (SILO)?

The LOI covers an open-label Single Ascending Dose (SAD) study and an open-label Multiple Ascending Dose (MAD) study in healthy subjects.

What services will Allucent provide to Silo Pharma under the proposed agreement (SILO)?

Allucent would provide clinical operations, pharmacovigilance, data management, biostatistics, clinical pharmacology modeling & simulation, and medical writing.

Is the agreement between Silo Pharma and Allucent binding (SILO)?

No; the announcement describes a non-binding Letter of Intent and indicates the parties intend to negotiate a Master Services Agreement and Work Order.

Does the LOI include payment terms for Silo Pharma's Phase 1 program (SILO)?

Yes; the LOI outlines proposed payment conditions, including an upfront amount for direct service fees and pass-through costs reconciled against final invoices.